




Searching News Database: Baxalta
HSMN NewsFeed - 6 Jan 2023
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
HSMN NewsFeed - 26 Apr 2022
Halozyme Commences Tender Offer for All Outstanding Shares of Common Stock of Antares Pharma
Halozyme Commences Tender Offer for All Outstanding Shares of Common Stock of Antares Pharma
HSMN NewsFeed - 13 Apr 2022
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
HSMN NewsFeed - 4 Nov 2019
Halozyme Announces Actions To Focus Strategy On ENHANZE(R) Drug Delivery Technology
Halozyme Announces Actions To Focus Strategy On ENHANZE(R) Drug Delivery Technology
HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
HSMN NewsFeed - 21 Feb 2019
Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
HSMN NewsFeed - 5 Mar 2018
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
HSMN NewsFeed - 4 Dec 2017
Astellas Appoints João Carlos de Britto as General Manager of Astellas Farma Brasil
Astellas Appoints João Carlos de Britto as General Manager of Astellas Farma Brasil
HSMN NewsFeed - 3 Oct 2017
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
HSMN NewsFeed - 1 Sep 2016
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
HSMN NewsFeed - 1 Aug 2016
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly